10-KPeriod: FY2021

THERMO FISHER SCIENTIFIC INC. Annual Report, Year Ended Dec 31, 2021

Filed February 24, 2022For Securities:TMO

Summary

Thermo Fisher Scientific Inc. (TMO) reported strong performance in its 2021 fiscal year, marked by significant revenue growth and an expanding business scope, notably through strategic acquisitions. The company, a leader in serving science, demonstrated resilience and adaptability, particularly in supporting the global response to the COVID-19 pandemic with essential diagnostic and therapeutic products and services. The acquisition of PPD, Inc. in December 2021 significantly bolstered the company's Biopharma Services capabilities, enhancing its end-to-end offering for pharmaceutical and biotechnology clients. This, along with other strategic acquisitions and continued organic growth across its four key segments – Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services – positions TMO for continued expansion. The company's diversified business model and commitment to innovation remain central to its strategy for driving growth and addressing complex scientific and healthcare challenges.

Financial Highlights

56 data points
Beta

Revenue

$39.21B

Net Income

$7.72B

19.7% Net Margin

EPS (Diluted)

$19.46

Total Assets

$95.12B

Cash & Equivalents

$4.49B

Free Cash Flow

$6.79B

Financial Statements
Beta
Revenue$39.21B
R&D Expenses$1.41B
SG&A Expenses$8.01B
Operating Expenses$29.18B
Operating Income$10.03B
Interest Expense$536.00M
Net Income$7.72B
EPS (Basic)$19.62
EPS (Diluted)$19.46
Shares Outstanding (Basic)394.00M
Shares Outstanding (Diluted)397.00M

Key Highlights

  • 1Thermo Fisher Scientific achieved substantial revenue growth in 2021, increasing by 22% to $39.21 billion, driven by strong performance across all end markets and significant contributions from COVID-19 related products and services.
  • 2The company completed the transformative acquisition of PPD, Inc. for $15.99 billion, significantly expanding its clinical research services capabilities within the Laboratory Products and Biopharma Services segment.
  • 3Organic revenue growth was robust at 17%, demonstrating the company's underlying business strength beyond acquisitions and currency impacts, with particular strength noted in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.
  • 4The Life Sciences Solutions segment saw a significant revenue increase of 28% (organic growth of 23%), driven by demand for COVID-19 diagnostics, biosciences products, and bioproduction capabilities supporting vaccine and therapy manufacturing.
  • 5The company reported strong profitability with GAAP operating income increasing by 29% to $10.03 billion and adjusted operating income increasing by 27% to $12.14 billion, leading to a 28% increase in adjusted EPS to $25.13.
  • 6Strategic investments in innovation and commercial capabilities, alongside productivity improvements, contributed to an expansion in operating income margins across most segments.
  • 7The company generated substantial free cash flow of $6.81 billion, supporting its capital allocation strategy which includes strategic acquisitions, share repurchases, and dividends.

Frequently Asked Questions

The primary drivers of Thermo Fisher Scientific's substantial revenue growth in 2021 were the broad-based demand across its key end markets (pharmaceutical and biotech, academic and government, industrial and applied, healthcare and diagnostics) and the significant contribution from products and services supporting the global response to the COVID-19 pandemic, including diagnostic testing and assistance in vaccine and therapy development and manufacturing.

The acquisition of PPD, Inc. significantly strengthens Thermo Fisher Scientific's position as a comprehensive provider of services to the pharmaceutical and biotechnology industries. PPD's clinical research services enhance TMO's ability to support customers throughout the entire drug development process, from early research to commercial manufacturing, accelerating innovation and increasing customer productivity.

While positive impacts from COVID-19 related sales are expected to continue into the next year, Thermo Fisher acknowledges that the duration and extent of future revenues from these specific sales are uncertain and will depend on customer testing demand and the ongoing need for therapies and vaccines. The company continues to monitor these trends closely.

Thermo Fisher Scientific believes it has a readily available supply of raw materials from various sources and that no single supplier is material. They employ strategies, including the use of alternative materials, to mitigate the effects of fluctuations in raw material and fuel prices. However, the company acknowledges risks related to reliance on sole or limited sources of supply and potential disruptions due to external events.